Dr. Yun Chen is a Principal Investigator and Doctoral Supervisor recruited through the prestigious Hundred-Talent Program at Sun Yat-sen University. He earned his Ph.D. at the University of Oklahoma Health Science Center, followed by postdoctoral research at the renowned Moores Cancer Center, UC San Diego. With a strong commitment to advancing medical research, Dr. Chen has contributed to a number of influential studies published in top-tier journals, including Blood, Cell Reports Medicine, Journal of Advanced Research, and Journal of Hematology and Oncology.
Dr. Chen’s primary research focuses on the molecular mechanisms underlying rare pediatric hematologic malignancies?JMML. His work aims to establish innovative disease models and develop targeted therapies to improve outcomes for these challenging conditions. By exploring the pathogenesis of these cancers and the role of tyrosine kinase inhibitors in precision medicine, Dr. Chen is pioneering new approaches to treatment that could significantly alter the clinical landscape for children with rare blood cancers.
?
?
Working Experience:
1/2025-present: Research Fellow, The Seventh Affiliated Hospital of Sun Yat-sen University.
3/2018-12/2024: Associate Research Fellow, The Seventh Affiliated Hospital of Sun Yat-sen University.
8/2015-3/2018: Postdoc employee, Moores Cancer Center. UC San Diego.????
?
?
Education:
8/2010 – 7/2015?Ph.D. Department of Pathology, The University of Oklahoma Health Science Center.
9/2008 – 7/2010 MS Graduate student, majoring in molecular biology and biochemistry, College of Life Sciences, Jilin University.
9/2004 – 9/2008 Bachelor of Science in Biotechnology, College of Life Sciences, Jilin University.
?
Research focuses:
1.? Mechanistic studies of rare pediatric hematologic diseases
2.??Disease modeling and organoid development
3.??Drug discovery and targeted therapy development
4.??Translational and clinical research
?
Publications:
1.? Na Li#; Stefanie Steiger#; Yao Guo#; Muzheng Li#; Zheqi Wen; Mingcheng Huang; Chuyu Xie; Shan Jiang; Dengyang Zhang; Yuming Zhao; Liuting Yu; Xiaohua Wang; Zhihua Zheng*; Zhizhuang Joe Zhao*; Yun Chen*; Tubular epithelial cell-derived Flt3L is required for type 1 conventional dendritic cell (cDC1) activation and expansion in promoting the recovery in acute kidney injury, Journal of Advanced Research, 2025, in press.
2.? Han Zhong Pei#; Yao Guo#; Yuming Zhao#; Dengyang Zhang; Zhiguang Chang; Jingfeng Zhou; Suk-Hwan Baek; Zhizhuang Joe Zhao*; Chun Chen*; Yun Chen*; FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia, Cancer Letters, 2025, 611(217446).?
3.??Chen, Yun#; Chen, Liguang#; Yu, Jian; Ghia, Emanuela M; Choi, Michael Y; Zhang, Ling; Zhang, Suping; Sanchez Lopez, Elsa; Widhopf, George F , II; Messer, Karen; Rassenti, Laura Z; Jamieson, Catriona; Kipps, Thomas J*; Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-kappa B to repress autocrine STAT3 activation in chronic lymphocytic leukemia, Blood, 2019, 134(13): 1084-1094.?
4.? Dengyang Zhang*, Chunxiao He*, Yao Guo*, Jianfeng Li, Bo Li, Yuming Zhao, Liuting Yu, Zhiguang Chang, Hanzhong Pei, Ming Yang, Na Li, Qi Zhang, Yulong He, Yihang Pan, Zhizhuang Joe Zhao#, Changhua Zhang#, Yun Chen#; Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor, BMC Medicine, 2022, 20:257.?
5.? Yuming Zhao#, Chunxiao He#, Dengyang Zhang#, Yao Guo, Zhiyong Peng, Liuting Yu, Na Li, Chun Chen*, Zhizhuang Joe Zhao*, Yun Chen*; Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML, Exp Hematol Oncol, 2023, 12:20.?
6.? Chunxiao He#, Zhiyong Peng#, Dengyang Zhang#, Yao Guo, Tianqi Liang, Yuming Zhao, Liuting Yu, Qi Zhang, Zhiguang Chang, Yan Xiao, Na Li, Hongman Xue, Shunjie Wu, Zhizhuang Joe Zhao*, Changhua Zhang*, Yun Chen*; Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia. Biochem Pharmacol, 2023, 213:115588.?
7.? Han Zhong Pei#, Zhiyong Peng#, Xiaomei Zhuang#, Xiaobo Wang, Bo Lu, Yao Guo, Yuming Zhao, Dengyang Zhang, Yunjun Xiao, Tianshun Gao, Liuting Yu, Chunxiao He, Shunjie Wu, Suk-Hwan Baek*, Zhizhuang Joe Zhao*, Xiaojun Xu*, Yun Chen*; miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia, Cell Death Discov, 2023, 9:249.?
8.? Chen, Yun#; Guo, Yao; Zhao, Wanke; Ho, Wanting Tina; Fu, Xueqi; Zhao, Zhizhuang Joe*; Identification of an orally available compound with potent and broad FLT3 inhibition activity, Oncogene, 2016, 35(23): 2971-2978.?
9.? Chen, Yun#; Guo, Yao#; Han, Jiayu; Ho, Wanting Tina; Li, Shibo; Fu, Xueqi; Zhao, Zhizhuang Joe*; Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity, Journal of Hematology & Oncology, 2012, 5: 39.?
10.?Guo, Yao#; Chen, Yun#; Xu, Xuesong; Fu, Xueqi*; Zhao, Zhizhuang Joe*; SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells, Journal of Hematology & Oncology, 2012, 5:72.?
Email: [email protected]